RVU120
Phase 2Small molecule
RVU120 is one of 124 small molecule programs targeting Anemia. It is currently in Phase 2.
3
Indications
7
Total Trials
6
Active Trials
123
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
364 competitors in Myelodysplastic Syndrome
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Venclexta
AbbViePhase 3
Fludara
SanofiPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Idamycin
PfizerPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cellcept
RochePhase 3
Aranesp
AmgenPhase 3
Novantrone
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed/Refractory AML2 trials
Advanced Solid Tumors1 trial
Myelofibrosis1 trial
Myelodysplastic Syndrome1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RVU120. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRyvu Therapeutics SA